Recombinate 01
Recombinate Kit
Product Images NDC 0944-2845
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Recombinate (NDC 0944-2845). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Recombinate 02
Recombinate 03
Recombinate 04
Recombinate 05
Recombinate 06
Recombinate 07
Recombinate 08
Recombinate 09
Recombinate 10
Recombinate 11
Recombinate 12
Recombinate 13
Recombinate 14
Recombinate 15
This appears to be a product label for a sterile water for injection solution that is intended to be used to reconstitute another product. The solution comes in a single-dose container, and cautionary instructions are provided such as the need to ensure the solution is clear and the recommendation to add a suitable solute to make it isotonic if used for intravascular injection. The product is nonpyrogenic.*
Recombinate 16
RECOMBINATE is an antihemophilic factor used for intravenous administration only. It should be stored in a refrigerator at 36° to 46°F (2° to 8°C) or at room temperature up to 86°F (30°C). Once reconstituted, it should not be refrigerated. The medication does not contain any preservatives. The package insert should be read before using this medication. It is manufactured by Baxalta US Inc. with the U.S. License No. 2020 RcOnly. Lot number, expiration date, date of the dose, and time of the dose fields are available to be filled out on the packaging.*
Recombinate 17
This appears to be a description of a medical product named "RECOMBINATE". The text includes information on how to use and store the product, including directions for use and storage temperatures. The product seems to be related to treating hemophilia and has a confidential patient registration system in place. The text also includes a company name "Baxter Healthcare Corporation" and a license number "2020" related to the product. However, there is insufficient information to provide a full description of the product's benefits and application.*
Recombinate 18
RECOMBINATE is an antihemophilic factor (recombinant) indicated for intravenous administration only. It should be stored in a refrigerator at 36° to 46°F (2° to 8°C) or at room temperature up to 86°F (30°C). Reconstituted RECOMBINATE should not be refrigerated and contains no preservative. The direction for use is available in the package insert. This product is produced and distributed by Baxalta US Inc. The lot and expiration dates are specified in the text.*
Recombinate 19
This is a description of a medical product with the text obtained by . The text contains information about the product's contents, storage conditions, and usage directions, along with a trademark and license number of the manufacturer. The product is indicated for administration with a double-ended needle and a spike, and it is recommended to store the product in a refrigerator or at room temperature, depending on the temperature range. The risks and benefits of the product should be discussed between patients and physicians.*
Recombinate 20
This appears to be a label for a vial of RECOMBINATE, a medication used for intravenous administration to treat bleeding disorders caused by low levels of clotting Factor VIII. The label provides information on the lot number, expiration date, and storage instructions. There is also a mention of a package insert with directions for use.*
Recombinate 21
This text is a product label for Recombinate, an Antihemophilic Factor (Recombinant) used for treating Hemophilia A. It contains information about the storage of the product, directions for use, and possible side effects. It also includes a unique product code (0030942843108) and the manufacturer's information.*
Recombinate 22
RECOMBINATE is a medication used for intravenous administration to treat hemophilia A and B. It is stored in refrigeration at 36 to 46°F (2°t0 8°C) or at room temperature up to 86°F (30°C). After reconstitution, it should not be refrigerated. The medication does not contain preservatives and should be used with caution. The medication's packaging contains the required instructions for use.*
Recombinate 23
This is a description of a medical product called "Recombinant," mainly used for antihemophilic factor deficiency. It comes with a double-ended needle and fitter spike, and it must be refrigerated between 38 to 46 degrees Fahrenheit. The package contains instructions for use and a patient notification system. The list of contents includes Oz il, and it is manufactured by Baxalta US Inc. Any patient, before using this product, must discuss with their physician the possible benefits and side effects, such as calcium, sodium, or histidine. The numerical codes 6196 0dd and 0030942844105 are also present.*
Recombinate 24
This is a product label for Recombinate, an antihemophilic factor (recombinant) used for intravenous administration. It includes a lot number, expiration date, and instructions for proper storage both before and after reconstitution. There are also warnings about not refrigerating after reconstitution and directions to read the package insert. The label is produced by Baxalta US Inc. and includes a trademark symbol.*
Recombinate 25
This appears to be a description of a medication, likely for a form of hemophilia or blood clotting disorder. The text includes instructions for use and storage, as well as a phone number to enroll in a confidential patient notification system. However, much of the text is garbled and non-readable due to errors.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
